Eli Lilly news in 2026: 30 dated events
The latest Eli Lilly event on this page is dated Nov 16, 2026. globenewswire.com reported: Stipple Bio Announces Multi-Target Multi-Modality Oncology Research Collaboration with Lilly.
Get Eli Lilly's live signals in Claude or ChatGPT, or by API
What changed at Eli Lilly this week? Use Autobound signals for lilly.com.- Dated events
- 30
- Last 90 days
- 30
- Latest
- Nov 16, 2026
Source: Autobound Signal API · 114 signals tracked for Eli Lilly · updated
News · latest 10
Latest Eli Lilly news
Showing 10 of 30 dated events. The Signal API returns all of them.
Get them with one API call- Richter Partners with U.S. Pharma Giant to Advance Women’s Health$15M · With Gedeon Richter
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one...Eli Lilly announced detailed 52-week results from its Phase 3b TOGETHER-PsA clinical trial evaluating the concomitant use of Taltz and Zepbound.
- Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight lossEli Lilly and Company announced positive Phase 3 clinical trial results for Foundayo (orforglipron) for the treatment of moderate-to-severe obstructive sleep apnea.
- Lilly and Hims & Hers expand access to FDA-approved Lilly medicinesWith Hims & Hers Health, Inc.
- Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolioEli Lilly and Company reported third-quarter 2026 net income of $6.5 billion.
- After obesity, Eli Lilly is set for a big neurosciences pushEli Lilly is developing remternetug, a phase III investigational amyloid-targeting therapy for subcutaneous delivery to treat Alzheimer's disease.
- Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trialEli Lilly and Company announced positive topline results from the Phase 3 TRANSCEND-T2D-2 clinical trial evaluating retatrutide in adults with type 2 diabetes.
Showing 10 of 30 dated events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Eli Lilly with the Signal API
One POST /v1/companies/enrich call with lilly.com returns Eli Lilly news signals (news), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"lilly.com","signal_types":["news"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real News records, as a CSV.
Same industry
News at related companies
Questions about Eli Lilly news
What is the latest news on Eli Lilly?
What is going on with Eli Lilly?
Page updated , the date of the newest row on this page.
Source. News articles about the company, one source link per event.
Method. Stories about the same event within 14 days merge into one row. Noise (lists, stock tips, recaps) is removed.
Data as of .